Results 51 to 60 of about 6,429 (163)
Generation of an Oncolytic Herpes Simplex Virus 1 Expressing Human MelanA [PDF]
Frontiers in Immunology, 2019 Robust anti-tumor immunity requires innate as well as adaptive immune responses. We have shown that plasmacytoid dendritic cells develop killer cell-like activity in melanoma cell cocultures after exposure to the infectious but replication-deficient herpes simplex virus 1 (HSV-1) d 106S.
Jan B. Boscheinen +14 more
openaire +5 more sources
Updates on intratumoral therapies in melanoma
Cancer, Volume 132, Issue 13, 1 July 2026.Abstract Intratumoral therapies provide an opportunity for novel strategies in the management of advanced melanoma. These approaches deliver concentrated doses of therapeutic immune agents directly into individual tumor(s), achieving local tumor control and induction of systemic antitumor immune responses while minimizing the risk of immune‐related ...
Vincent T. Ma +12 more
wiley +1 more source
Biomedicines, 2017 Oncolytic virotherapy represents a novel therapeutic strategy in the treatment of gastrointestinal malignancies. Oncolytic viruses, including genetically engineered and naturally occurring viruses, can selectively replicate in and induce tumor cell ...
Daniel H. Ahn, Tanios Bekaii-Saab
doaj +1 more source
Cancer Science, Volume 117, Issue 7, Page 2007-2020, July 2026.OncoVV‑shHSP70, a vaccinia virus silencing HSP70, demonstrated potent antitumor efficacy in colorectal cancer cell lines, as well as in syngeneic, xenograft, and humanized mouse models. In cell lines, oncoVV‑shHSP70 promoted viral oncolysis and cytokine production through a self‑reinforcing cycle of ROS‑autophagy. In both CT26 and SW620‑humanized mouse
Rentao Yuan +8 more
wiley +1 more source
Thymopentin enhances adenoviral oncolytic therapy by regulating macrophages and CD8+ T cells
Communications MedicineBackground Oncolytic viruses are cancer therapies that selectively replicate in tumors, deliver therapeutic genes, and stimulate immune responses. Combining these viruses with immune-boosting agents could enhance their effectiveness.
Lingkai Kong +13 more
doaj +1 more source
Cancer Science, Volume 117, Issue 7, Page 1961-1974, July 2026.In murine tongue cancer models, T‐mB7‐1, a triple‐mutated oncolytic herpes simplex virus type 1 (HSV‐1) engineered to express soluble B7‐1, suppresses cervical lymph node metastasis and improves survival, addressing a major prognostic determinant in oral squamous cell carcinoma (OSCC).
Akinari Sugauchi +11 more
wiley +1 more source
Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy [PDF]
Frontiers in Microbiology, 2014 Oncolytic viruses (OV) are a class of antitumor agents that selectively kill tumor cells while sparing normal cells. Oncolytic herpes simplex virus (oHSV) has been investigated in clinical trials for patients with the malignant brain tumor glioblastoma for more than a decade.
Ning, Jianfang, Wakimoto, Hiroaki
openaire +5 more sources
Viruses, 2022 Herpes simplex virus type 1 (HSV-1) is the only FDA- and EMA- approved oncolytic virus, and accordingly, many potential oncolytic HSVs (oHSV) are in clinical development.
Kiira Kalke +8 more
doaj +1 more source
Biologics: Targets & Therapy, 2018 Kenneth Lundstrom PanTherapeutics, Lutry, Switzerland Abstract: Oncolytic viruses have demonstrated selective replication and killing of tumor cells.
Lundstrom K
doaj
Pigment Cell &Melanoma Research, Volume 39, Issue 4, July 2026.ABSTRACT The 2025 Cure Ocular Melanoma (CURE OM) Global Science Meeting took place in Amsterdam, The Netherlands on October 25th, 2025. Several promising drug candidates are in development; however, there is still an urgent need for better prevention, detection, and treatment of uveal melanoma.
Andrew E. Aplin +18 more
wiley +1 more source